Vertex Pharmaceuticals (MA)'s $300,000 A Year Drug Is Denied, And Medicaid Patients Sue

2014-07-18
BioSpace
LITTLE ROCK, Ark.—Vertex Pharmaceuticals Inc.'s $300,000-a-year cystic-fibrosis drug has sparked a legal battle here, where the state's Medicaid program is restricting access to the expensive therapy. In a lawsuit filed in Arkansas federal court last month, three people suffering from the fatal lung disease allege Medicaid officials have for two years denied them access to Kalydeco because of its cost. The plaintiffs allege state... Help employers find you! Check out all the jobs and post your resume.
机构
适应症
靶点
-
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。